Pharmaceuticals News and Research

RSS

MicroStockProfit.com releases investment report featuring Hemispherx Biopharma

MicroStockProfit.com announces an investment report featuring biopharmaceutical company Hemispherx Biopharma Inc. The report includes financial, comparative and investment analysis, and industry information you need to know to make an educated investment decision.

12 May 2010

New approach to harness and modulate enzyme activity

An Arizona State University graduate student, Jinglin Fu, in collaboration with Biodesign Institute researchers Neal Woodbury and Stephen Albert Johnston, has pioneered a technique that improves on scientists' ability to harness and modulate enzyme activity.

12 May 2010

Drug-releasing stents do not result in fewer deaths or subsequent heart attacks after angioplasty

Drug-releasing stents are more effective than bare metal stents at keeping a blocked artery open after angioplasty, but the difference does not result in fewer deaths or subsequent heart attacks after the procedure, according to a review of recent studies.

12 May 2010

Evotec first-quarter operating loss decreases 93% to € 1.5 m

Evotec AG today reported financial results and corporate updates for the first quarter of 2010.

12 May 2010

Meda acquires European rights to new imiquimod formulation for AK from Graceway Pharmaceuticals

“We have very good experience with Aldara in Europe and we look forward to provide AK patients with a new product with improved tolerability that builds on the efficacy of imiquimod”

12 May 2010

Response Genetics, GSK sign non-exclusive license agreement for BRAF mutational analysis technology

Response Genetics, Inc., a company focused on the development and sale of molecular diagnostic tests for cancer, today announced it has signed a non-exclusive license agreement with GlaxoSmithKline ("GSK"). Under the terms of the agreement, GSK gains certain rights to Response Genetics' proprietary PCR analysis technology and diagnostic expertise to assess BRAF gene mutations in human tumor samples. Payments will be made to Response Genetics upon achivement of agreed-to milestones.

12 May 2010

Optivia Biotechnology launches OptiDDI Suite for assessing transporter-related DDIs

Optivia Biotechnology Inc., a leading provider of in vitro transporter assay services, today announced the launch of the OptiDDITM Suite, a novel assay panel that assesses the most clinically significant transporter-related drug-drug interactions (DDIs), as identified by the International Transporter Consortium (ITC) in its report "Membrane Transporters in Drug Development" (Nature Reviews-Drug Discovery, March 2010).

12 May 2010

New computer-based tool developed to benefit cancer patients

Cancer patients and doctors are finally getting on the same page about cancer survivorship, thanks to a free new tool that can benefit anyone who has been diagnosed with cancer.

12 May 2010

PharmedOut to host conference to explore influence of pharmaceutical industry on medical education

PharmedOut, an initiative aimed at increasing physician access to unbiased information about drugs, will host a conference to explore the issues of pharmaceutical industry funding on continuing medical education. The conference, "Prescription for Conflict: Should Industry Fund Continuing Medical Education?" will be held June 25, 2010 at Georgetown University.

12 May 2010

MIT featured in U.S. Equity News

Micro Identification Technologies, Inc., a leader in rapid bacterial identification, today announces it was recently featured in an editorial published by U.S. Equity News that covers the history of bacteria, its life threatening effects, and publicly traded companies leading the fight against harmful bacteria.

12 May 2010

Group worries about proposals to allow drug marketing on social media websites

The Center for Digital Democracy is concerned about proposals to allow pharmaceutical companies to market drugs on social media websites. Such a change is under examination by the Food and Drug Administration, the National Journal's Tech Daily Dose reports.

12 May 2010

Pacira Pharmaceuticals receives $11.25M credit facility from GE Capital, Healthcare Financial Services

GE Capital, Healthcare Financial Services today announced it has provided an $11.25 million credit facility to Pacira Pharmaceuticals, Inc. The financing provides working capital, and facilitates advances toward regulatory approval and preparation for commercialization of Pacira's EXPAREL™ program.

12 May 2010

ProBioGen signs contract with Virdante Biopharmaceuticals

ProBioGen AG, a technology and service provider for the development and production of biopharmaceutical drug substances today announced signing a contract with Virdante Biopharmaceuticals, Inc., a US-based biopharmaceutical development company.

12 May 2010

OXiGENE reports consolidated net loss of $11.0M for first-quarter 2010

OXiGENE, Inc., a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, reported financial results for the quarter ended March 31, 2010, and presented an update on recent clinical and corporate progress.

12 May 2010

Update on Nymox Pharmaceutical's Phase 3 program for NX-1207

Nymox Pharmaceutical Corporation provided an update today on the Company's Phase 3 program for NX-1207, Nymox's investigational drug for benign prostatic hyperplasia. The most recent Safety Monitoring Committee meeting of April 30, 2010 for the Phase 3 U.S. pivotal trials of NX-1207 indicated no significant safety concerns for the trials to date.

12 May 2010

MaxCyte STX Scalable Transfection System acquired by CCS Cell Culture Service

MaxCyte, Inc., the pioneer in scalable, high performance cell loading systems, is pleased to announce that CCS Cell Culture Service GmbH has acquired the MaxCyte® STX™ Scalable Transfection System to develop and optimize cells for the pharmaceutical industry.

12 May 2010

FDA approves delivery of Cefepime in B. Braun's DUPLEX System

The U.S. Food and Drug Administration recently approved an application that permits B. Braun Medical Inc. (B. Braun) to deliver FDA-approved 1g and 2g Cefepime for Injection USP and Dextrose Injection USP in B. Braun's DUPLEX® Drug Delivery System.

From B. Braun Melsungen AG 12 May 2010

CEVEC, Aragen Bioscience announce strategic license agreement

CEVEC Pharmaceuticals, the developer of a novel human expression system derived from amniocytes, and Aragen Bioscience, Inc., a California based contract research and development organization, announced today the signing of a strategic license agreement. This license enables Aragen Bioscience to offer its clients custom recombinant human cell lines expressing biotherapeutic proteins and antibodies as well as the transient and stable production of preclinical and clinical grade material.

12 May 2010

Australian TGA approves Acetadote for treatment of paracetamol poisoning

Cumberland Pharmaceuticals Inc. and Phebra Pty Ltd. today announced that Acetadote® (acetylcysteine) Injection has been granted regulatory approval for marketing and sale in Australia. Acetadote, an injectable drug used to treat acetaminophen (paracetamol) overdose, was approved by the Therapeutic Goods Administration (TGA), the government agency responsible for regulating drugs and medical devices in Australia.

12 May 2010

Tianyin third-quarter revenue up 60%

Tianyin Pharmaceutical Co., Inc.,, a biopharmaceutical company that specializes in the modernized traditional Chinese medicine and branded generics today announced fiscal results for its third quarter ended March 31, 2010.

12 May 2010